Pharmacyclics falls after presentation


Shares of Pharmacyclics (PCYC -1.6%) are lower in afternoon trading after the company's presentation at the JPMorgan Healthcare Conference.

Ibrutinib highlights from the "conclusions" slide: Drug "demonstrated safety, tolerability, and durability of response at ≥ one year ... in treatment naive and relapsed/refractory CLL/SLL;" serious AEs decreased after one year of treatment; median DOR not yet reached in extension study.

See also: PCYC notifies investors of relevant changes to NCCN Clinical Practice Guidelines

For more on ibrutinib (Imbruvica) in CLL/SLL, see here.

From other sites
Comments (2)
  • danceprometheus
    , contributor
    Comments (27) | Send Message
     
    Reasons it fell?
    13 Jan 2014, 11:09 PM Reply Like
  • danceprometheus
    , contributor
    Comments (27) | Send Message
     
    Reasons it fell?
    13 Jan 2014, 11:09 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs